Table IV.
Clinical outcomes of low-risk patients in the three groups.
| Clinical outcome | Pre-ERCP som [n=36; n (%)] | Post-ERCP som [n=61; n (%)] | Control [n=47; n (%)] | P-value |
|---|---|---|---|---|
| PEP | 0 | 2 (3.3) | 3 (6.4) | 0.371a |
| Hyperamylasemia | 16 (16.7) | 13 (21.3) | 8 (17) | 0.858 |
a
Pre-ERCP som vs. control: P=0.254, Post-ERCP som vs. control: P=0.651;
PEP, post-endoscopic retrograde cholangiopancreatography pancreatitis; pre-ERCP som, pre-endoscopic retrograde cholangiopancreatography somatostatin administration; post-ERCP som, post-endoscopic retrograde cholangiopancreatography somatostatin administration.